The startup is developing a novel analgesic drug that targets specific pain pathways to provide effective relief for patients experiencing chronic pain. By collaborating with academic institutions and healthcare professionals, the company aims to enhance patient outcomes and improve quality of life for those suffering from pain.

Chordia Therapeutics is focused on developing targeted therapies in oncology to improve treatment outcomes for cancer patients. The company aims to address the limitations of current cancer treatments by utilizing precision medicine approaches to tailor therapies based on individual tumor profiles.

Junten Bio develops cell therapies utilizing induced regulatory T cells to achieve immune tolerance in organ transplantation, specifically targeting liver and kidney transplants. Their approach aims to mitigate immune rejection, allowing patients to reduce reliance on immunosuppressive drugs post-transplant.

The startup develops oligonucleotide therapeutics utilizing a licensed cross-linked modified nucleic acid technology that binds strongly to target mRNA, enhancing drug efficacy while minimizing hepatotoxicity risks. This approach provides hospitals with effective treatment alternatives for patients facing diseases that currently lack viable drug options.

The startup develops multifunctional biopharmaceuticals targeting rare diseases, utilizing a streamlined drug development process for new biologics. This approach significantly reduces the time required for drug discovery, providing cost-effective alternatives to existing treatments.

Modalis is a biotech company that utilizes CRISPR technology to develop targeted therapeutics for genetic disorders, specifically focusing on conditions like congenital muscular dystrophy. Their approach aims to provide precise gene editing solutions to address the underlying genetic causes of these diseases.